Use of sorafenib in two metastatic renal cell cancer patients with end-stage renal impairment undergoing replacement hemodialysis

Tumori

Volumn 95, Issue 4, 2009, Pages 542-544

  Ferraris, Elisa ^a   Di Cesare, Pamela ^a   Lasagna, Angioletta ^a   Paglino, Chiara ^a   Imarisio, Ilaria ^a   Porta, Camillo ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Dialysis; End stage renal impairment; Sorafenib

Indexed keywords

ALPHA INTERFERON; BISPHOSPHONIC ACID DERIVATIVE; INTERLEUKIN 2; SORAFENIB; ZOLEDRONIC ACID;

ADULT; ADVANCED CANCER; ARTICLE; ASTHENIA; BONE METASTASIS; BRAIN RADIATION; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURGERY; CASE REPORT; CLEAR CELL CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; DYSPNEA; FOLLOW UP; GASTRITIS; HEART MUSCLE ISCHEMIA; HEMODIALYSIS; HUMAN; KIDNEY CARCINOMA; KIDNEY FAILURE; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; NEUROTOXICITY; PRESSURE; RECURRENT CANCER; SIDE EFFECT;

EID: 70350076873     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160909500425     Document Type: Article

References (17)

1. Hepps D, Chernoff A: Risk of renal insufficiency in African-Americans after radical nephrectomy for kidney cancer. Urol Oncol, 24: 391-395, 2006.
2. Healy KA, Marshall FF, Ogan K: Cytoreductive nephrectomy in metastatic renal cell carcinoma. Exp Rev Anticancer Ther, 6: 1295-1304, 2006. (Pubitemid 44304697)
3. Van de Poll-Franse LV, Houterman S, Janssen-Heijnen ML, Dercksen MW, Coebergh JW, Haak HR: Less aggressive treatment and worse overall survival in cancer patients with diabetes: a large population based analysis. Int J Cancer, 120: 1986-1992, 2007.
4. Négrier S: Role of arterial hypertension in kidney cancer. Progr Urol, 13 (Suppl 2): 1197-1198, 2003.
5. Maertens S, Van Den Noortgate NJ: Kidney in old age. Acta Clin Belgica, 63: 8-15, 2008.
6. Finkel KW, Foringer JR: Renal disease in patients with cancer. Nature Clin Pract Nephrol, 3: 669-678, 2007. (Pubitemid 350146950)
7. Mangoni AA, Jackson HD: Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol, 57: 6-14, 2004.
8. Buzio C, De Palma G, Passalacqua R, Potenzoni D, Ferrozzi F, Cattabiani MA, Vanenti L, Borghetti A: Effectiveness of very low doses of immunotherapy in advanced renal cell cancer. Br J Cancer, 76: 541-544, 1997. (Pubitemid 27331222)
9. Strumberg D, Clark JW, Awada A, Moore MJ, Richly H, Hendlisz A, Hirte HW, Eder JP, Lenz HJ, Schwartz B: Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist, 12: 426-437, 2007. (Pubitemid 46698720)
10. Nexavar summary of product characteristics. Available at http://www.emea.europa.eu/humandocs/PDFs/EPAR/nexavar/H-690-PI-en.pdf (Accessed 26 August 2008).
11. Kane RC, Farrell AT, Saber H, Tang S, Williams G, Liang C, Booth B, Chidambaram N, Morse D, Sridhara R, Garvey P, Justice R, Pazdur R: Sorafenib for the treatment of advanced renal cell cancer. Clin Cancer Res, 12: 7271-7278, 2006.
12. Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, Faghih M, Brendel E, Voliotis D, Haase CG, Schwartz B, Awada A, Voigtmann R, Scheulen ME, Seeber S: Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol, 23: 965-972, 2005. (Pubitemid 46202316)
13. Clark JW, Eder JP, Ryan D, Lathia C, Lenz HJ: Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res, 11: 5472-5480, 2005. (Pubitemid 41060823)
14. Moore M, Hirte HW, Siu L, Oza A, Hotte SJ, Petrenciuc O, Cihon F, Lathia C, Schwartz B: Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol, 16: 1688-1694, 2006.
15. Smith W, Marbury T, Kipnes M, Cihon F, Lettieri J, Mazzu A: Effects of renal impairment on the pharmacokinetics of sorafenib and its metabolites. AACR Annual Meeting, Los Angeles (USA), 934 (abstract), 2007.
16. Parsa VK: Safety and efficacy of sorafenib therapy in patients with metastatic kidney cancer with impaired renal function. ASCO Genitourinary Cancers Symposium, Chicago (USA), 365 (abstract), 2008.
17. Golshayan AR, George S, Elson P, Wood L, Garcia A, Bukowski RM, Rini BI: VEGF-targeted therapy in metastatic renal cell carcinoma patients with renal insufficiency. ASCO Genitourinary Cancers Symposium, San Francisco (USA), 364 (abstract), 2008.